Catch up on today’s top five analyst downgrades with this list compiled by The Fly: 1. Global Blood Therapeutics (GBT) downgraded to Neutral from Overweight at JPMorgan with analyst Tessa Romero seeing a “meaningful” long-term market opportunity for Oxbryta but says the feedback was “more mixed” on the overall profile/clinical experience with the drug. 2. Sandstorm Gold (SAND) downgraded to Underperform from Sector Perform at RBC Capital with analyst Josh Wolfson predicting that production will start to decline at Sandstorm Gold’s royalty asset base near-term, and growth is linked to non-royalty Hod Maden output becoming its dominant source of cash flow. 3. Maximus (MMS) downgraded to Outperform from Strong Buy at Raymond James with analyst Brian Gesuale believing that recent absolute gains for shares of Maximus and relative gain will temporarily moderate along with COVID tailwinds that have been a major element of the story. 4. ResMed (RMD) downgraded to Neutral from Buy at Citi with analyst John Deakin-Bell saying given that the recall of Philips’ (PHG) DreamStation CPAP devices creates an opportunity for ResMed to fill the void in the short term and potentially take share in the long-term, he has raised his FY22-23 EPS estimates and price target. 5. BRF S.A. (BRFS) downgraded to Neutral from Buy at Goldman Sachs with analyst Thiago Bortoluci saying the outlook for input costs has “sequentially deteriorated” as rainfall volume in the Mid-West region has not improved as originally expected. This list is just a portion of The Fly’s full analyst coverage. To see The Fly’s full Street Research coverage, (click here.):(http://thefly.com/streetResearch.php)
previous post